Alembic Pharmaceuticals Limited has informed the Exchange about Transcript
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals reported Q4 FY'25 revenue of Rs. 1,770 crores, up 17% year-on-year, with EBITDA of Rs. 286 crores (16% margin, up 9%) and net profit of Rs. 157 crores. Full-year FY'25 revenue grew 7% to Rs. 6,672 crores, EBITDA was Rs. 1,053 crores (up 10%), and net profit was Rs. 583 crores. The US generics business grew 20% in Q4 to Rs. 508 crores, ex-US generics surged 43% to Rs. 375 crores, and India business rose 8% to Rs. 545 crores, with Animal Health remaining a strong performer at 19% growth. The board declared a dividend of Rs. 11 per share (550%). Management guided for FY'26 US growth in mid-teens (~15%), ROW at 12-15%, API at ~10%, and India at double-digits, with R&D spend of Rs. 600-650 crores and maintenance CAPEX of Rs. 400-450 crores.
Management indicated that as new facilities (Pithampur, peptide block, injectable line) ramp up utilization, EBITDA margins should expand from the current ~15% toward 18-20% over the next couple of years, which is a positive signal for shareholders. The healthy dividend, low debt-equity ratio of 0.23, and expected reduction in working capital-driven borrowings also support a stable outlook, though near-term margins may stay around 70% gross due to product mix.